Annual EBITDA
-$26.78 M
-$177.00 K-0.67%
December 31, 2023
Summary
- As of February 25, 2025, PROF annual EBITDA is -$26.78 million, with the most recent change of -$177.00 thousand (-0.67%) on December 31, 2023.
- During the last 3 years, PROF annual EBITDA has fallen by -$7.29 million (-37.37%).
- PROF annual EBITDA is now -227.22% below its all-time high of -$8.18 million, reached on December 31, 2015.
Performance
PROF EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$8.72 M
-$1.17 M-15.56%
September 1, 2024
Summary
- As of February 25, 2025, PROF quarterly EBITDA is -$8.72 million, with the most recent change of -$1.17 million (-15.56%) on September 1, 2024.
- Over the past year, PROF quarterly EBITDA has dropped by -$1.54 million (-21.50%).
- PROF quarterly EBITDA is now -104960.24% below its all-time high of -$8300.00, reached on December 31, 2014.
Performance
PROF Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$31.24 M
-$2.45 M-8.50%
September 1, 2024
Summary
- As of February 25, 2025, PROF TTM EBITDA is -$31.24 million, with the most recent change of -$2.45 million (-8.50%) on September 1, 2024.
- Over the past year, PROF TTM EBITDA has dropped by -$3.83 million (-13.99%).
- PROF TTM EBITDA is now -11267.18% below its all-time high of -$274.80 thousand, reached on September 30, 2014.
Performance
PROF TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
PROF EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -0.7% | -21.5% | -14.0% |
| 3 y3 years | -37.4% | -21.5% | -14.0% |
| 5 y5 years | -104.6% | -21.5% | -14.0% |
PROF EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -0.7% | +6.5% | -87.6% | +10.1% | -32.2% | at low |
| 5 y | 5-year | -113.8% | +6.5% | -407.6% | +10.1% | -149.1% | at low |
| alltime | all time | -227.2% | +6.5% | <-9999.0% | +10.1% | <-9999.0% | at low |
Profound Medical EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$8.72 M(+15.6%) | -$31.24 M(+8.5%) |
| Jun 2024 | - | -$7.55 M(+5.1%) | -$28.79 M(+5.1%) |
| Mar 2024 | - | -$7.18 M(-7.9%) | -$27.40 M(+2.3%) |
| Dec 2023 | -$26.78 M(+0.7%) | -$7.79 M(+24.2%) | -$26.78 M(+13.3%) |
| Sep 2023 | - | -$6.27 M(+1.9%) | -$23.64 M(-6.3%) |
| Jun 2023 | - | -$6.16 M(-6.0%) | -$25.22 M(+3.1%) |
| Mar 2023 | - | -$6.55 M(+41.0%) | -$24.47 M(-4.4%) |
| Dec 2022 | -$26.60 M(-7.1%) | -$4.65 M(-40.9%) | -$25.60 M(-16.5%) |
| Sep 2022 | - | -$7.86 M(+45.6%) | -$30.65 M(+8.6%) |
| Jun 2022 | - | -$5.40 M(-29.8%) | -$28.22 M(-3.7%) |
| Mar 2022 | - | -$7.69 M(-20.7%) | -$29.31 M(+2.3%) |
| Dec 2021 | -$28.65 M(+46.9%) | -$9.70 M(+78.4%) | -$28.65 M(+8.3%) |
| Sep 2021 | - | -$5.43 M(-16.3%) | -$26.46 M(-0.2%) |
| Jun 2021 | - | -$6.49 M(-7.6%) | -$26.53 M(+6.9%) |
| Mar 2021 | - | -$7.03 M(-6.4%) | -$24.80 M(+27.2%) |
| Dec 2020 | -$19.50 M(+55.6%) | -$7.51 M(+36.5%) | -$19.50 M(+28.7%) |
| Sep 2020 | - | -$5.50 M(+15.3%) | -$15.15 M(+10.4%) |
| Jun 2020 | - | -$4.77 M(+177.6%) | -$13.73 M(+7.8%) |
| Mar 2020 | - | -$1.72 M(-45.6%) | -$12.73 M(+1.5%) |
| Dec 2019 | -$12.53 M | -$3.16 M(-22.5%) | -$12.54 M(+6.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2019 | - | -$4.08 M(+8.0%) | -$11.81 M(+5.9%) |
| Jun 2019 | - | -$3.78 M(+147.5%) | -$11.15 M(-0.6%) |
| Mar 2019 | - | -$1.53 M(-37.1%) | -$11.22 M(-13.8%) |
| Dec 2018 | -$13.09 M(-0.4%) | -$2.43 M(-29.2%) | -$13.02 M(+2.3%) |
| Sep 2018 | - | -$3.42 M(-10.9%) | -$12.73 M(-4.7%) |
| Jun 2018 | - | -$3.84 M(+15.7%) | -$13.36 M(+3.9%) |
| Mar 2018 | - | -$3.32 M(+55.4%) | -$12.86 M(+4.1%) |
| Dec 2017 | -$13.14 M(+15.5%) | -$2.14 M(-47.3%) | -$12.35 M(-8.9%) |
| Sep 2017 | - | -$4.06 M(+21.4%) | -$13.56 M(+10.1%) |
| Jun 2017 | - | -$3.34 M(+18.9%) | -$12.31 M(+6.6%) |
| Mar 2017 | - | -$2.81 M(-15.9%) | -$11.55 M(+0.8%) |
| Dec 2016 | -$11.38 M(+39.1%) | -$3.34 M(+18.8%) | -$11.46 M(+18.5%) |
| Sep 2016 | - | -$2.81 M(+8.9%) | -$9.67 M(+9.4%) |
| Jun 2016 | - | -$2.58 M(-4.9%) | -$8.84 M(-12.2%) |
| Mar 2016 | - | -$2.72 M(+74.3%) | -$10.07 M(+36.7%) |
| Dec 2015 | -$8.18 M | -$1.56 M(-21.3%) | -$7.36 M(+26.7%) |
| Sep 2015 | - | -$1.98 M(-48.1%) | -$5.81 M(+41.5%) |
| Jun 2015 | - | -$3.81 M(>+9900.0%) | -$4.11 M(+1297.3%) |
| Mar 2015 | - | -$10.80 K(+30.1%) | -$293.90 K(+3.8%) |
| Dec 2014 | - | -$8300.00(-97.0%) | -$283.10 K(+3.0%) |
| Sep 2014 | - | -$274.80 K | -$274.80 K |
FAQ
- What is Profound Medical annual EBITDA?
- What is the all time high annual EBITDA for Profound Medical?
- What is Profound Medical annual EBITDA year-on-year change?
- What is Profound Medical quarterly EBITDA?
- What is the all time high quarterly EBITDA for Profound Medical?
- What is Profound Medical quarterly EBITDA year-on-year change?
- What is Profound Medical TTM EBITDA?
- What is the all time high TTM EBITDA for Profound Medical?
- What is Profound Medical TTM EBITDA year-on-year change?
What is Profound Medical annual EBITDA?
The current annual EBITDA of PROF is -$26.78 M
What is the all time high annual EBITDA for Profound Medical?
Profound Medical all-time high annual EBITDA is -$8.18 M
What is Profound Medical annual EBITDA year-on-year change?
Over the past year, PROF annual EBITDA has changed by -$177.00 K (-0.67%)
What is Profound Medical quarterly EBITDA?
The current quarterly EBITDA of PROF is -$8.72 M
What is the all time high quarterly EBITDA for Profound Medical?
Profound Medical all-time high quarterly EBITDA is -$8300.00
What is Profound Medical quarterly EBITDA year-on-year change?
Over the past year, PROF quarterly EBITDA has changed by -$1.54 M (-21.50%)
What is Profound Medical TTM EBITDA?
The current TTM EBITDA of PROF is -$31.24 M
What is the all time high TTM EBITDA for Profound Medical?
Profound Medical all-time high TTM EBITDA is -$274.80 K
What is Profound Medical TTM EBITDA year-on-year change?
Over the past year, PROF TTM EBITDA has changed by -$3.83 M (-13.99%)